Exceltox Laboratories, LLC.

Exceltox Laboratories, LLC. was paid $8.87M by Medicaid between Jan 2018 and Nov 2024, across 42 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 76% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#77 of 561

Median peer was paid$222K

This provider vs. median40×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	47,342	$1.05M
2019	50,559	$615K
2020	36,939	$2.29M
2021	71,905	$2.83M
2022	41,049	$1.88M
2023	3,666	$181K
2024incomplete	1,477	$30K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	76%	111,599	44,588	$6.73M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	4.9%	6,954	1,988	$438K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	4.1%	19,494	5,576	$367K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.1%	35,868	15,240	$272K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.2%	3,275	2,332	$104K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.1%	246	244	$96K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	523	176	$67K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	3,697	892	$59K
80348		<1%	4,196	784	$52K
80365		<1%	4,189	783	$52K
80361		<1%	4,193	784	$52K
80356		<1%	4,191	783	$52K

30 more codes

80372		<1%	4,115	$51K
80362		<1%	4,160	$51K
80346		<1%	4,190	$50K
80354		<1%	3,687	$45K
80353		<1%	4,192	$42K
80358		<1%	4,189	$42K
83992		<1%	4,191	$37K
80324		<1%	3,687	$36K
80373		<1%	4,188	$36K
80359		<1%	4,191	$36K
80352		<1%	3,775	$31K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	2,013	$22K
87486		<1%	246	$9K
87581		<1%	246	$9K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	246	$7K
80325		<1%	472	$5K
80299		<1%	539	$5K
80350		<1%	498	$5K
81227		<1%	122	$2K
80369		<1%	1,605	$1K
80368		<1%	1,605	$891.85
81226		<1%	104	$443.70
81479	Unlisted molecular pathology procedure	<1%	240	$358.20
81241		<1%	81	$105.62
81240		<1%	81	$91.96
80367		<1%	1,532	$76.92
81355		0%	100	$0.00
81401		0%	108	$0.00
81291		0%	81	$0.00
81225		0%	28	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCHAVEZ, BRIAN (PARTNER)